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ABSTRACT 
Breast cancer is a heterogeneous disease. Aggressive subtypes are characterized by faster 
growth rates, increased capability to invade and metastasize, leading to poorer clinical 
outcomes. In this thesis, we use a molecular epidemiology approach to investigate the 
association between risk factors and aggressive breast cancer defined by tumor characteristics, 
intrinsic subtypes, mode of detection, and survival. Using a variety of methods, we analyzed 
data from well-characterized breast cancer cohorts in Sweden, genome-wide association 
studies, and gene expression profiling of tumors. 
In Paper I, we found that breast cancer genetic load, defined by rare deleterious variants in 31 
breast cancer genes, and unlike common variants, is positively associated with unfavorable 
tumor characteristics, patient survival, and mode of detection.  
In Paper II, we observed that women with low breast cancer risk defined by the Tyrer-Cuzick 
risk score were more likely to develop aggressive tumors. We computed a low-risk gene 
expression profile that was consistently associated with worse prognosis. In addition, our 
analysis showed that increased proliferation rather than estrogen status underlie this 
association. 
In Paper III, we examined gene expression profiles in a subset of aggressive breast cancer 
tumors, known as interval cancers. By taking mammographic density and intrinsic PAM50 
subtypes into account, we found an interval cancer gene expression profile to be associated 
with immune subtypes in breast cancer, particularly those involving interferon response. 
In Paper IV, we show that breast cancer has a shared immune-related genetic component with 
celiac disease, an autoimmune disorder. In consistency with previous epidemiological findings, 
we found that a higher genetic load for celiac disease was associated with lower breast cancer 
risk.  
Overall, this thesis aims to provide scientific evidence towards a better understanding of the 
factors underlying the development of aggressive breast cancers that could shed light on the 
design of better preventative strategies aimed at lowering disease mortality.   
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1 Background 
Breast cancer is the most commonly occurring malignancy among women, and its incidence is 
increasing.[1] In 2018, over two million new cases and more than 600,000 deaths were 
estimated worldwide.[2] Global differences in incidence and mortality are largely explained by 
age and country-level income.[3] The increasing trend in incidence is mainly attributed to 
reproductive and lifestyle patterns such as older age at first birth, decrease in childbearing and 
breastfeeding, lower physical activity, and obesity.[4, 5] Breast cancer survival has improved 
over the last decades as the result of the development of adjuvant and targeted therapies,[6] and 
introduction of mammographic screening,[7] primarily in more developed countries.[8] 
Nevertheless, strong differences in survival and other clinical outcomes are observed between 
groups of patients,[9] particularly in women diagnosed with triple-negative breast cancer for 
whom optimal therapies are lacking.[10] 
 
 
Figure 1. Breast cancer heterogeneity. Clinical, pathological, and molecular features depict the 
heterogeneous nature of breast cancers. 
 
From both a biological and a clinical perspective, breast cancer is consider to be a 
heterogeneous disease that can be characterized by a number of clinical, pathological, and 
molecular features (Figure 1). Generally, breast carcinomas are divided into ductal or lobular, 
according to their localization, and as in situ or invasive. The most common type of breast 
carcinomas are invasive ductal carcinomas (IDC) that account for more than 50% of invasive 
cases, followed by invasive lobular carcinoma (ILC), observed in 5% to 15% of patients.[11, 
12] The main clinico-pathological features used to describe invasive breast carcinomas are 
tumor grade (undifferentiated vs well-differentiated), tumor stage (larger tumor size and 
number of lymph node involved), and cellular receptor status (negative vs positive). Based on 
these features, breast cancers can be categorized according to the WHO recommendations.[13, 
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14] The current state of knowledge supports that breast cancers are a mixture of multiple and 
diverse dynamic entities, from which a phenotype emerges based on the interplay between 
intrinsic tumor characteristics and host factors, imposing great challenges for diagnosis and 
treatment.[15] 
Because of the observed heterogeneity in clinical outcomes, tumors more likely to display 
aggressive features and to have poor prognosis require special attention. Therefore, patient 
stratification is important for adequate clinical management, i.e. treatment decision and patient 
care.[16, 17] Also, an accurate tumor classification can allow epidemiological and functional 
studies to unravel mechanisms of carcinogenesis and disease progression,[18] which can prove 
useful for design of early intervention studies towards prevention. In this thesis, we present 
results in the field of molecular epidemiology of invasive breast cancer, and discuss how our 
findings contribute towards better a understanding of the relationship between risk factors and 
disease aggressiveness. 
1.1 BREAST CANCER AGGRESSIVENESS  
Aggressive subtypes of breast cancer can be described as tumors with higher capacity for 
proliferation, invasiveness, and metastasis, leading to poorer prognosis and ultimately, higher 
mortality rates. An imperative task in breast cancer research is to identify factors associated 
with poorer outcomes, in order to effectively reduce breast cancer burden. The following sub-
sections describe subsets of invasive breast cancers defined according to clinico-pathological 
information (tumor characteristics), gene expression profiling (classification into intrinsic 
subtypes), and the mode of detection in the context of mammographic screening in Sweden 
(interval cancers as compared to screen-detected). 
1.1.1 Tumor characteristics 
During the recent decades, large efforts have been made to identify markers that can facilitate 
to predict prognosis (clinical outcomes such as recurrence and death) and therapy response. 
Breast cancer tumor characteristics are the most broadly studied prognosticators and represent 
a relevant measure of aggressive disease.[16] Stage, tumor size, lymph-node involvement, and 
histological grade, are accepted as prognostic markers, where tumors of larger than 20 mm, 
node-involvement, and distant metastasis (stage IV tumors) exhibit poorer prognosis.[19] 
Based on molecular targets such as hormone nuclear receptors of estrogen (ER) and 
progesterone (PR), and the human epidermal growth factor receptor 2 (HER2), which are 
commonly measured by immunohistochemistry lab techniques, tumors can be classified into 
hormone positive (HR+) when expression of either ER or PR is detected,[20] as HER2-
positive, or as triple-negative when lacking expression of either marker. HR+ status has been 
associated with lower risks of mortality independently of demographic and other tumor 
characteristics.[21, 22] In contrary, 15 to 25 % of breast cancers overexpressing HER2, a 
transmembrane tyrosine kinase receptor involve in cell growth,[23] are associated with poorer 
survival,[24] whereas 10% to 20% of cases classified as triple-negative tumors are associated 
with worse prognosis.[25] 
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1.1.2 Intrinsic subtypes 
The development of high-throughput molecular technologies has allowed for the 
characterization of biological samples at very high resolution. In 2000, Perou and colleagues 
introduced the concept of ‘molecular intrinsic’ breast cancer subtypes base on the idea that the 
observed phenotypic diversity could be described by distinct gene expression patterns.[26] By 
comparing expression profiles from 22 paired sample specimens, the authors could identify an 
‘intrinsic’ subset comprised of 496 genes for which variation across samples was larger than 
the variation within pairs of samples from the same tumors.  Using hierarchical clustering, 
samples could be separated into two main groups distinctive on their ER receptor status, but 
with a considerable amount of residual variation within each group, indicating the existence of 
additional breast cancer subtypes. 
Following this principle, classification tools with clinical relevance have been developed. A so 
called PAM50 classifier[27] was found to predict breast cancer subtypes based on a fifty gene 
expression signature into five previously reported breast cancer subtypes: luminal A, luminal 
B, HER2-enriched, basal-like, and normal-like. Analysis of more than 500 tumors concluded 
that the multiple levels of biological variation could be captured by four main PAM50 subtypes 
and explain a fair amount phenotypic heterogeneity.[28] The PAM50 subtypes have also been 
shown to be robust in spite of intra-tumor heterogeneity,[29] in line with the original proposal 
by Perou and colleagues. More importantly, PAM50 subtypes were clinically validated by 
predicting significant differences in patient survival independently of clinical predictors (i.e. 
tumor characteristics), with HER2- and basal-like the tumors with poorer outcome.[30] In 
addition, PAM50 subtypes were shown to provide more clinically relevant information than 
histopathological parameters and with the potential to improve treatment strategies. Table 1 
shows a summary of the relation between the main intrinsic subtypes and the most common 
immunohistochemical (IHC) markers and clinical outcome. 
 
Table 1. Overall description of breast cancer intrinsic subtypes by IHC markers and clinical 
outcome. 
Intrinsic subtype Main IHC markers Clinical outcome (survival) 
Luminal A ER+, PR+, HER2-, low proliferation Good 
Luminal B ER+, PR+, HER2+/-, high 
proliferation 
Intermediate-poor 
HER2-enriched ER-, PR-, HER2+ Poor 
Basal-like ER-, PR-, HER2-, basal marker+  Poor 
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1.1.3 Interval cancers 
Interval cancer is defined as breast cancers diagnosed after a negative mammographic 
screening and before the next programmed screening.[31] Upon blinded re-review of 
mammogram images, interval cancers can be classified into ‘true’ cases with no signs of 
malignant lesions, or ‘missing’ cases where re-examination reveals abnormal signs.[32] Based 
on epidemiological surveillance in mammographic screening programs, ‘true’ interval cancers 
have been observed to occur in 14.7% of cases at annual screening intervals, 17-30% at 
biennial, and 32-38% in triennial programs, and about 20-25% of cases were missed at 
screening.[33]  
It has been proposed that ‘true’ interval cancers correspond to fast growing tumors and 
therefore are enriched in aggressive breast cancer subtypes.[34-36] When compared with 
screen-detected tumors, interval cancers are more likely to have larger size, lymph node 
involvement, higher grade, to be triple-negative or HER2-postive, hormone receptor-negative, 
and are associated with poorer survival.[32, 33] Molecular characterization of tumors using 
sequencing technologies showed that interval cancers are associated with molecular intrinsic 
subtypes of poor survival independently of mammographic density.[37] In that same study, 
interval cancers were found to be enriched in luminal B and basal-like tumors. Moreover, 
association with higher mutational load in TP53, PPP1R3A, and KMT2B cancer-related genes 
as well as differences in somatic copy number aberrations were found, suggesting that key 
biological features drive aggressiveness of interval cancers.  
Because mammographic dense tissue affects screening specificity, i.e. increases false-negative 
cases (a phenomenon referred to as ‘masking’), interval cancers in women with low 
mammographic density are more likely to be enriched in ‘true’ interval cancers (Figure 2). 
Previous studies in our group found pronounced differences when comparing invasive tumors 
with low mammographic density (≤ 20%) on interval cancers versus screen-detected regarding 
lymph node involvement, ER-negative status, HER2-postive, progesterone receptor-negative 
and triple-negative.[38] 
 
Figure 2. Graphical description of breast cancer mode of detection. Arrows indicate a breast 
cancer diagnosis within a mammographic screening setting, and shaded area represents high 
mammographic density. Tumors can be missed at screening due to a “masking effect” in high 
dense breasts. IC, interval cancer. SD, screen-detected breast cancer. 
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1.2 BREAST CANCER RISK FACTORS 
Breast cancer is a complex disease involving hereditary (genetic) and environmental (non-
genetic) risk factors. An essential task in cancer epidemiology is to identify and quantify the 
contribution of these risk factors on the disease development.  
1.2.1 Non-genetic risk 
Established risk factors for breast cancer are related to age, estrogen exposure, reproductive 
history, and mammographic density. The relationship between the main non-genetic exposures 
and breast cancer risk is shown in Table 2. Mammographic density has been discovered to be 
a strong and independent risk factor for breast cancer[39], and seem to be independent of 
molecular subtypes.[40, 41] Family history of breast cancer is an important risk factor 
reflecting the complex interaction between genetic and environmental factors involved in 
breast cancer etiology. It is defined as having first-degree (e.g. mother, sister, or daughter) or 
second-degree relatives that have been diagnosed with breast cancer. Family history is 
associated with an intermediate to high risk independently of mammographic density.[42] The 
risk is about doubled in first-degree than second-degree family history, and the risk is higher 
risk when both mother and sister have been affected.[43]   
 
Table 2. Main breast cancer risk by non-genetic risk factors. 
Risk factor Exposure Effect Aggressive subtype 
Sex Female ↑↑↑↑  
Age Older (> 40 or >60 years old) ↑↑↑  
Family history Yes vs No  ↑↑↑ BRCA, basal-like 
Mammographic density High vs Low ↑↑↑  
Benign breast disease Yes vs No ↑-↑↑↑  
Age at menarche At age < 12 years old ↑  
Age at menopause At age > 55 years old  ↑  
Parity Yes vs No ↓ BRCA, basal-like 
Age at first birth Older age (> 35 years old) ↑  
Breast feeding No vs yes, (e.g. < 1 year) ↑↑ Basal-like 
Postmenopausal obesity Body mass index > 30 Kg/m2 ↑  
Oral contraceptive use Ever vs Never ↑  
HRT Ever vs Never ↑↑ No (Luminal A) 
Oophorectomy Yes vs No ↓↓↓  
Arrows represent the direction and strength of association: ↕↕↕↕ very strong, ↕↕↕ strong, ↕↕ intermediate, ↕ low. 
 
Hormonal exposure, mainly of estrogen, has a pivotal role in the risk to develop breast 
cancer.[44] Other conventional risk factors that most presumably act by modifying hormone 
exposure are: female sex and older age with the largest risk estimates, followed by low to 
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intermediate relative risks associated with age at natural menopause, age at menarche, age at 
first birth, breast feeding, parity, postmenopausal obesity, oophorectomy, and exogenous 
estrogen exposures such as oral-contraceptive use and hormone/estrogen-replacement 
therapy.[43]  
As breast cancer is a heterogeneous disease, efforts are made to identify specific risk factors, 
particularly on aggressive subtypes.[45] Full-term pregnancy and breastfeeding were the most 
important protective factors in hereditary (BRCA carriers) breast cancer.[46] A study from our 
group assessing the heterogeneity of different risk factors including reproductive and genetic 
factors, also found breastfeeding to be protective factor mainly for basal-like tumors, which 
were enriched in BRCA mutations when compared with luminal A tumors; ever use of hormone 
replacement therapy was differentially associated with increased risk of luminal A tumors.[47] 
Regarding mammographic density, the risk for breast cancer does not seem to differ by ER or 
HER2 status.[40] 
1.2.2 Genetic risk 
A genetic (inherited) component in breast cancer is well established in the etiology of breast 
cancer.[48] Estimation of heritability based on twin studies found 25 to 31 percent to be 
explained by genetic factors.[49-51] Currently, high-risk women are primarily identified on the 
basis of family history and mutation screening of the BRCA1[52] and BRCA2[53] genes located 
on chromosome 17 and 13, respectively, which convey a lifetime risk between 50 to 85% and 
account for approximately 15% of familial breast cancer.[54] 
A large effort to investigate the genetic component of breast cancer has taken place since the 
discovery of the BRCA1/2 genes.[55] Genetic risk variants can be classified into high, 
moderate, and low risk, based on their penetrance expressed in relative risks (RR) as: 1) high 
risk if RR > 4, 2) moderate risk if RR between 2 to 4, and 3) low risk if RR < 1.5.[56] Base on 
their allele frequency, genetic variants are classified into common (>1%) or rare (<1%). Put 
together, it has been observed that highly pathogenic variants are rare and that susceptibility 
variants with lower risk are more frequent (Figure 3). Moderate-to-high risk variants have been 
mainly identified in familial breast cancer cases through genetic linkage studies followed by 
positional cloning, and candidate gene-panel sequencing of unrelated individuals which search 
for protein-coding deleterious variants found at a frequency <1% in general population.[57] On 
the other hand, common variants have been identified through Genome Wide Association 
Analysis (GWAS). While rare variants tend to be of higher penetrance, common variants are 
often of low-penetrance. 
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Figure 3. Penetrance and frequency of breast cancer genetic variants. Variants within the 
shadowed area, thought to explain breast cancer heritability. Variants below the lower 
boundary (rare and low-penetrance) are hard to be detected and of little utility, while variants 
above the upper boundary (common and high-penetrance) are subjected to strong negative-
selection, thus difficult to be observed. Inspired by Manolio, T.A., et al.[58] RR, relative risks. 
 
Common variants 
Initiated with the discovery of common predisposition variants by the first breast cancer GWAS 
in 2007,[59] low-risk variants have been identified in large cohorts under the hypothesis of a 
‘common-disease common-variants’.[57] A series of successful studies with continuously 
increasing number of participants, allow for pooled analysis through international 
collaborations.[60] The largest GWAS in European population up to date analyzed 118,474 
breast cancer cases and 96,201 controls, as well as BRCA1 mutations carriers, 9,414 affected 
and 9,494 unaffected.[61] The study included participants from 82 studies from the Breast 
Cancer Association Consortium (BCAC), and from 60 studies from the Consortium of 
Investigators of Modifiers of BRCA1/2 (CIMBA). The authors reported 32 new loci were 
identified in addition to the 178 loci reported in previous GWAS from the BCAC.[62, 63] The 
210 variants were found to explain 54.2, 37.6 and 26.9% of the genome-wide chip heritability 
for luminal-A-like, triple-negative, and BRCA1 carriers, respectively, and about 18% of the 
familiar risk for invasive breast cancer.[61] Analysis on the genetic correlation between breast 
cancer subtypes showed that luminal A-like breast cancer is less correlated with triple-negative 
and BRCA1 subtypes (0.46 and 0.39, respectively), while highest correlation was observed for 
the BRCA1 subtype with triple-negative and HER2-enriched-like subtypes (0.84 and 0.80, 
respectively) (Figure 4). 
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Figure 4. Genetic correlation between breast cancer intrinsic-like subtypes, estimated through 
LDSC regression. Reprinted by permission from Springer Nature. Zhang et al 2020.[61] 
 
When combined into polygenic risk scores (PRSs),[64] common variants are able to explained 
a larger proportion of phenotypic variation and have proven useful for risk stratification.[65, 
66] Recently, a PRS including 330 single nucleotide polymorphisms (SNPs) was found to 
confer 83% to 65% higher risk for luminal-A-like and triple-negative subtypes, 
respectively.[61] These results are similar to a previous PRS based on 313 SNPs that was 
associated with 61% higher risk of overall breast cancer, 4.37-fold risk of ER-positive, and 
2.78-fold risk of ER-negative breast cancer on women in the highest centile as compared with 
women in the middle PRS quintile.[67] 
 
Rare variants 
It has been proposed that the “missing heritability” observed in GWAS studies could be 
potentially explained by rare variants with moderate-to-high risk effects that require the 
systematic characterization of a large number of samples.[68] The advent of Next Generation 
Sequencing (NGS) technologies, that allow for reading entire coding regions of DNA (exon-
sequencing), or whole genomes (whole-genome sequencing), has enable the discovery of novel 
breast cancer germline pathogenic variants which could not have been identified through 
family studies.[69-72] Multigene (sequencing) panels are proving to be useful in identifying 
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breast cancer susceptibility genetic variants involved in DNA repair (similar to the BRCA 
genes), cell-cycle control or mitotic signal transduction pathways.[73]. Carriers of high- and 
moderate-risk germline mutations in genes such as BRCA1, BRCA2, CHEK2 and PALB2, have 
been found to be predisposed to specific subtypes of breast cancer.[74-77] In particular, 
mutated BRCA1 gene is highly enriched for basal-like tumors,[78, 79] and ATM and CHEK2 
have been observed to be associated with higher risk of ER-negative disease.[80] In addition 
to the BRCA genes, germline mutations in PALB2, RAD51D, and BARD1 have been found to 
be associated with triple-negative breast cancer.[81] Combined, mutations in high-to-moderate 
risk genes account for 9% to 14% of triple-negative cases and were associated with more 
aggressive phenotypes, as found through gene-panel sequencing of patients unselected for 
family history of breast cancer.[82, 83] 
While sequencing studies allow for identification of rare deleterious variants, GWAS variants 
lie most presumably on gene regulatory elements.[57]  Interestingly, sequencing of exon-intron 
boundaries of 56 genes identified through GWAS studies, only found weak evidence of rare 
deleterious variants being associated with breast cancer risk in non-BRCA families.[84] A 
similar conclusion was drawn from a large study sequencing 38 genes neighboring 38 leading 
GWAS SNPs.[85] However, this does not discard the possibility of finding regulatory variants 
conferring high risk effects on GWAS studies, and does not mean that all variants in protein-
coding regions are of high penetrance. 
 
Immune-related genetic factors 
Immune and inflammatory responses play a key role in the different stages of cancer 
disease.[86] It is possible that immune-related genetic variants affect breast cancer 
susceptibility by influencing immunosurveillance mechanisms and could potentially provide 
prognostic information, particularly on tumor subtypes with higher immunogenicity. For 
instance, studies on candidate genetic predisposition variants have found immune-related genes 
to be associated with ER-negative breast cancer.[87, 88]  
Large-scale genotyping initiatives have been undertaken in order to characterize the genetic 
architecture underlying the phenotypic variation of immune traits[89, 90] and the susceptibility 
to develop autoimmune diseases in which an altered immune response is exhibited.[91] These 
data sources represent an opportunity to explore the role of immune-related factors on breast 
cancer in order to identify common etiological and prognostic factors. Autoimmune diseases 
are known to be associated with breast cancer based on epidemiological data.[92] Celiac 
disease in particular, a gastrointestinal immune-mediate disease triggered by gluten intake, has 
been associated with reduced risk of breast cancer.[93, 94]. Base on this idea, overall trends or 
correlations between traits based on genomic variant information can be used to guide the 
search for shared etiological factors, also referred as pleiotropy.[95] For that, different 
methodologies have been proposed to exploit the ‘hidden’ information that can be capture from 
GWAS studies.[96-98] 
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1.3 MOLECULAR ASPECTS OF BREAST CANCER BIOLOGY 
This section aims to describe key concepts in cancer biology that provide a theoretical 
framework for the understanding of the observed molecular features in cancer, and with 
particular remarks on breast cancer. In this context, mutations are the thought as the main 
drivers of cancer cells (carcinogenesis), where biological features emerge (cancer hallmarks) 
in a complex and dynamic fashion (heterogeneity and evolution) (Figure 5). A separate section 
on immunogenicity, that in a sense provides a link between the former concepts, is also briefly 
described. 
1.3.1 Carcinogenesis 
Carcinogenesis, also known as tumorigenesis or oncogenesis, refers to the processes by which 
genomic alterations, acquired and/or inherited, lead to the formation of cancer cells.[99] 
Mutated genes driving this process are broadly classified into two categories according to their 
biological function: tumor-suppressor genes, which act as “guardians of the genome”, and 
oncogenes or proto-oncogenes. In breast cancer, a number of oncogenes (e.g. ErbB2, PI3KCA, 
MYC, and CCND1) and tumor-suppressor genes (BRCA1, BRCA2, PTEN, CHK2, NBS1, 
RAD50, PALB2, BRIP) have been identified.[100, 101]  
The prevailing theory of cancer proposes that for the formation of cancer cells, a stepwise 
acquisition of cancer-favoring mutations is required for the clonal evolution of cancer 
cells.[102-104] The nature of these mutations can be inheritance, DNA-damaging 
environmental factors, and consequence of errors in DNA replication.[105] Causal mutations 
are referred as driver mutations, to distinguish them from passenger or neutral mutations.[106, 
107] In a recent pan-cancer analysis 299 driver genes were identified, of which about 10% were 
found in more than half of the cancer types, while more than 50% of genes were unique to one 
subtype.[108] Still, the role of passenger mutations is debated,[109] as they may provide 
evolutionary advantages to intermediate cancer cell phenotypes.[110] Generally, mutational 
signatures provide valuable information on cancer etiology, prognosis, and potential 
therapeutic targets.[111] For instance, mutational load across cancer genomes was used to 
identify diagnostic and prognostic gene expression signals,[112] and to predict positive 
response to immunotherapy in different cancer types.[113]  
1.3.2 Cancer hallmarks 
By acquisition of key biological properties, called ‘cancer hallmarks’,[114, 115] abnormal cells 
are able to become tumorigenic and invasive. Cancer hallmarks include: sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming of 
energy metabolism, and evading immune destruction, all of which are underlined by two 
enabling characteristics: genome instability, and tumor-promoting inflammation. Tumors can 
also be conceptualized as tissues composed of multiple cell types that interact with the tumor 
microenvironment through signaling processes.   
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Figure 5. Molecular aspects of breast cancer biology. Mammary cells portray a unique 
mutational landscape (genotype); somatic mutations can trigger transformation into cancer 
cells, which evolve into a distinct breast cancer subtype through clonal evolution; 
Immunoediting events occur along this process. CSCs, cancer-stem cells; TME, tumor 
microenvironment. 
 
In the specific case of breast cancer, these principles can be used to describe breast cancer 
heterogeneity in a more coherent way by assigning tumor subtypes onto cancer hallmarks.[116] 
For instance, ‘sustaining proliferative signaling’ is proposed to be the principal mechanism 
driving tumors with hormonal (e.g. ER | PR positive, luminal A subtype) and growth receptor 
positivity (tumor with HER2+). Over-expressed proliferation markers such as TOP2A, Ki-67, 
and cell cycle genes can further differentiate [ER+ | PR+, HER2-] tumors into more aggressive 
subtypes. ‘Activating invasion and metastasis’ hallmark is more characteristic in tumors with 
poorer prognosis such as triple negative [ER-, PR- and HER2-] and basal like subtype, where 
basal markers such as cytokeratins are linked with tumorigenesis and metastasis. Properties 
related to the same hallmark, such as epithelial to mesenchymal transition processes and cell 
stemness, are enriched in triple negative tumors. Other breast cancer subtype that can be 
distinguished in relation with ‘Evading immune destruction’ cancer hallmark, is the so called 
interferon-rich tumors (accounting for ~10% of cases), a subset of triple-negative cancers with 
intermediate survival outcome. 
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1.3.3 Heterogeneity and evolution 
Biological features of cancer, such as intratumoral heterogeneity in breast cancinomas,[117] 
can be described from a developmental perspective.[118, 119] Under this paradigm, cancer cell 
populations (clones and sub-clones) arise from carcinogenic and tumorigenic events in an 
evolution-like process, which can explain fundamental differences between breast cancer 
subtypes at the single-cell level.[120] For instance, sub-clonal mutations identified in the AKT, 
FGFR, PIK3CA, and TP53 genes through multi-region NGS sequencing of breast cancer 
primary tumors, were found to explain aggressive phenotypes such as increased proliferation, 
chemoresistance, invasiveness, and metastasis.[121] Another theory to explain tumor 
heterogeneity forwarded in 1977, is the existence of different cells-of-origin,[122] referred as 
cancer stem cells (CSCs). Other models integrating clonal evolution and CSCs, to explain 
intratumoral heterogeneity, have also been proposed.[123] 
1.3.4 Immunogenicity 
Clonal selection is influenced by the host immune system in a process called immuoediting, 
which can be differentiated into three phases: elimination, equilibrium, and scape.[124] 
Elimination refers to the processes by which the innate effector cells and adaptive immune 
system lead newly formed cancer cell towards apoptosis.  The equilibrium phase is 
characterized by the acquisition of molecular modifications which allow malignant cells to 
avoid immune system detection and elimination. In the scape phase, tumor cells are capable of 
inducing an immunosuppressive microenvironment allowing further proliferation.[125]  
Immunogenicity of the tumor reflects the extent of immune response involvement and can be 
described by the presence of tumor infiltrating lymphocytes (TIL). For breast cancer in 
particular, TILs have been observed predominantly on triple-negative tumors, i.e. more than 
50% lymphocytic infiltrate, which correlates with better prognosis from each 10 percent 
increase in TIL; other breast cancer subtypes exhibit lower TIL levels and could benefit from 
TIL enhancing therapies.[126] Immunogenicity is determined by the ability of immune cells to 
recognize tumor-specific epitopes defining the antigenicity of a tumor. Higher mutational load 
is positively correlated with formation of tumor neoantigens, making them more immunogenic, 
and is usually higher on ER-negative tumors. Immunogenicity can also be enhanced by specific 
mutational signatures affecting DNA repair mechanism, as it is for BRCA genes linked to basal-
like tumors. Tumors with lower proliferation and genomic instability such as luminal subtype 
may result in lower antigenicity. However, heterogeneity in ER-positive tumors could be 
influenced by high genomic driver diversity favoring immune-scape mechanisms.[124] 
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2 Aims 
The overall aim of this thesis was to generate new knowledge on breast cancer epidemiology 
by leveraging of molecular data, with a particular focus on disease aggressiveness. The specific 
aims, corresponding to the constituent scientific papers included in this thesis, are the 
following: 
I. To evaluate the contribution of rare and common germline genetic variants on disease 
aggressiveness. 
II. To characterize tumor gene expression patterns behind the association between breast 
cancer risk, defined by the 5-year Tyrer-Cuzick risk score, and disease aggressiveness.  
III. To investigate underlying biological features of interval breast cancers independent of 
the PAM50 intrinsic subtypes. 
IV. To assess the genetic correlation and overlap between breast cancer and celiac disease. 
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3 MATERIALS AND METHODS 
In this thesis, we included women who participated in two breast cancer studies in Sweden 
designed to investigate risk factors, tumor characteristics, and clinical outcomes, among other 
aspects of breast cancer. After ethical approval and participant informed consent, detail level 
information was collected from questionnaires, medical records, and from linkage to high 
quality registers. Additionally, data from external studies in Swedish and European populations 
was used in some of the analysis. The following sections describe the study populations, data 
material and summary variables, study designs, and statistical methods used across the four 
papers. 
3.1 UNDERLYING STUDY POPULATIONS 
In all our studies, we included women recruited under the Linné-Bröst 1 (LIBRO-1) study. In 
papers II, III, and IV, we included women who participated in the KARolinska MAmmography 
Project for Risk Prediction of Breast Cancer (KARMA) study. In paper I and IV, some analyses 
were based on data obtained from The Breast Cancer Association Consortium (BCAC). Gene 
expression validation datasets obtained from two independent breast cancer cohorts, The 
Cancer Genome Atlas (TCGA), and the MERCK, are also briefly described. 
3.1.1 LIBRO-1 
The LIBRO-1 study has been described in previous publications.[38, 127] Briefly, it consists 
of women diagnosed with invasive breast cancer between January of 2001 and December of 
2008 in the Stockholm/Scotland regions of Sweden, who were alive in 2009. In total, more 
than 9,000 women were identified through the Regional Cancer register and invited, of which 
5,715 accepted to participate in the study. 
3.1.2 KARMA 
KARMA is a large and well characterized prospective breast cancer cohort.[128] It is derived 
from population-based mammographic-screening or clinical radiology examinations 
conducted at five participating hospitals from the Stockholm and Skåne regions of Sweden 
(Stockholm South General Hospital, Helsingborg Hospital, Skåne University Hospital, Lund 
Hospital, and Landskrona Hospital). Between January 2011 and March 2013, more than 
210,000 women were invited to participate. In total, more than 70,000 women with our without 
breast cancer diagnosis were included in study, of which approximately 3,000 have been 
diagnosed with invasive breast cancer.  
3.1.3 BCAC 
BCAC is the largest international initiative to characterize the genetic susceptibility of breast 
cancer (http://bcac.ccge.medschl.cam.ac.uk/). In our studies, we used GWAS summary results 
reported for overall, ER-positive, and ER-negative breast cancer risk, based on European 
population, here referred as GWAS summary statistics, which are further discussed in section 
3.2.4.3 Briefly, in Paper IV we used summary results published in 2015,[129] in which over 
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85,000 women of European ancestry (45,290 cases) were genotyped under the Collaborative 
Oncological Gene-Environment Study (COGS), using an Illumina iSelect SNP Array that 
covered 211,155 SNPs, the iCOGS.[130] In Paper I, we used GWAS summary results 
published in 2017,[62] where over 100,000 women of European ancestry (61,282 cases)  were 
genotyped using the iCOGS, or the OncoArray, an Illumina SNP array targeting more than 
500,000 genomic variants.[131] 
3.1.4 Ethical approvals 
All women participating in the LIBRO-1 and KARMA studies gave written informed consent 
to extract data from medical records and national registers, provided information on risk 
factors, and donated a blood sample for genetic analysis. The studies were approved by the 
Regional Ethical Review Board at Karolinska Institutet (LIBRO-1, DNR: 2009/254-31/4, 
amendments 2011/2010-32, and 2012/465-32; KARMA, DNR: 2010/958-31/1, amendment 
2013/2090-32), and were conducted in accordance with the Declaration of Helsinki. In brief, 
all personal data was pseudonymised by the Swedish National Board of Health and Welfare 
(in Swedish, Socialstyrelsen) and analyzed in secure local servers at the Department of Medical 
Epidemiology and Biostatistics, following data management guidelines. 
3.2 DATA MATERIAL 
Data material consisted of the main outcomes and exposures are described in this section. The 
main outcomes included tumor characteristics (all papers), breast cancer specific survival 
(Papers I and II), and interval cancers (Paper III). The main exposure variables were based on 
breast cancer risk factors (Paper II), genetic (Papers I and IV), and gene expression data (Papers 
II and III). 
3.2.1 Tumor characteristics, treatment, and survival  
Data on molecular markers was retrieved from medical and pathology records. ER and PR 
percentage staining was determined using radioimmunoassay or IHC techniques and 
dichotomized into positive (if ≥10%) or negative status, otherwise. HER2 status was 
dichotomized as negative status if protein expression from IHC/immuocytochemistry was 0 or 
1+, or higher, and no gene amplification by FISH, and assigned positive status if gene 
amplification by FISH was observed. Proliferation marker Ki67 was measured in hotspot 
regions following routine guidelines and was reported as low if percent staining <20%, or as 
high otherwise. Information on prior breast cancer diagnoses, lymph node involvement 
(dichotomized into positive or negative), tumor size diameter measured in millimeters, and 
tumor grade recorded using the Nottingham Histologic Grade system,  as well as treatment 
regimen (adjuvant chemotherapy, endocrine therapy, and radiotherapy) was obtained through 
the Swedish National Cancer Register (INCA)[132] and the Stockholm-Gotland Regional 
Breast Cancer Quality Register[133] through the Swedish personal identity numbers.[134] 
Information on date and breast cancer-specific cause of death (code “C50*”) was obtained from 
the Swedish Cause of Death Register.[135] 
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3.2.2 Risk factors  
Information on various aspects of women’s health was extracted from questionnaire data 
provided by each participant in the LIBRO-1 and KARMA study, at time of entry. Data on 
reproductive history, family history of breast cancer, exposure to exogenous estrogen (i.e. use 
of oral contraceptives, and hormone-replacement therapy) was obtained. This information was 
used to estimate absolute breast cancer risks (Tyrer-Cuzick score) in Paper III, as described 
below in section 3.3.3. 
3.2.3 Interval cancer and mammographic density 
In this thesis, we assessed mammographic screening history (i.e. dates at mammographic 
screening visits) to define breast cancer mode of detection (i.e. screen-detected or interval 
cancer). Screening information regarding data and outcome from each visit was obtained from 
the population-based mammography screening database[136] at the Stockholm-Gotland 
Regional Cancer Center. Since 1989, in Stockholm, all women aged 50 to 69 years have been 
invited to screening at 24-month intervals, and 2005, women aged 40 to 49 years have also 
been invited to screening at 18-month intervals. Breast cancer diagnosis from women regularly 
attending mammographic screening, were classified by mode of detection into interval cancers, 
or screen-detected breast cancer. Interval cancers were defined as breast cancer diagnosis 
occurring after a negative screening mammogram and before the next programmed screen. 
Screen-detected tumors were defined as breast cancer diagnosis occurring after a positive 
screening mammogram. Breast mammographic density, expressed in percentage (PD), was 
measured from mammograms of healthy breasts prior breast cancer diagnosis using a machine-
learning algorithm, STRATUS,[137] developed by our group.  
3.2.4 Genetic data  
Three types of germline genetic data were analyzed in this thesis: 1) sequencing data, 2) raw 
genotype data, and 3) GWAS summary statistics. The first type consisted of targeted 
sequencing of 31 breast cancer related genes to measure carriership of rare deleterious variants 
(section 3.3.1). The second and third type inform about common genetic variants across the 
genome that can be summarized into PRSs (section 3.3.2) or used to estimate genetic 
correlation (section 3.4.3).  
3.2.4.1 Sequencing data (Paper I) 
Germline DNA sequencing was performed in LIBRO-1 patients using a custom-made gene 
panel. The gene panel was design to target exome and intro/exon boundary regions of 31 genes 
breast cancer predisposition genes included in commercial gene panels.[80] DNA variant 
calling was obtained for 5,099 (99.55%) of 5,122 patients successfully sequenced at the Centre 
for Cancer Genetic Epidemiology, at University of Cambridge (see eMethods in Data 
Supplement 2, Paper I). In brief, the panel consisted of an amplicon-based (targeted) custom 
panel, applied to a NGS platform. The in total 1,350 amplicons and primer sequences used to 
target the intro/exon boundaries of the 31 genes are shown in Paper I, Table S1 in Data 
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Supplement 2. Library preparation (enrichment) was performed using the Fluidigm Access 
Array 48.48 system. Libraries were sequenced on a single lane of an Illumina platform (Hi-
Seq200) yielding 100-base paired-end reads. Bioinformatics processing of raw data consisted 
of reads alignment to a human reference genome (hg19) using the Burrows-Wheeler Aligner 
(BWA).[138] Variant calling was performed using the Genome Analysis Toolkit 
(GATK)[139] UnifiedGenotyper pipeline (see Figure S1, in Data Supplement 2, Paper I). A 
number of quality control and hard filtering criteria were applied to obtain high confidence 
variant calls for SNP, and INDELs, separately, as shown in Paper I, Supplementary Table 3. 
Rare variants were defined at <2% frequency. For annotation of variants (i.e. classification of 
variants into nonsense, frameshift, splicing, missense, etc.), the ANNOVAR[140] software was 
used. 
3.2.4.2 Raw genotype data (Paper I and IV) 
In this thesis, we used individual-level genotype data from women who participated in the 
LIBRO-1 or KARMA study, and that were genotyped as part of the iCOGS initiative.[129] In 
Paper I, a case-only study, more than 5,000 women diagnosed with breast cancer who 
participated in the LIBRO-1 study were included. These women were also included in paper 
IV, in addition to 5,433 women without cancer diagnosis (controls) who participated in the 
KARMA study. Women subjected to genotyping had donated blood samples at study entry. 
From these samples, germline DNA was extracted and genotyped using the iCOGS, a custom 
Illumina iSelect SNP array.[130] Because the array only targets approximately 200,000 
independent SNPs, a standard strategy is to impute genotypes at genome-wide coverage based 
on the principle of linkage disequilibrium (LD).[141] In our studies, imputation was performed 
using the IMPUTE version 2 software,[142] and a genome reference panel of densely 
genotyped individuals from the 1000 Genome Project, which contains information for over 88 
million common variants.[143]  
3.2.4.3 GWAS summary statistics (Paper I and IV) 
We used data on common genetic variation of breast cancer and celiac disease measured in 
large GWAS studies, referred as GWAS summary statistics. Advantages of this type of data is 
its de-personalized nature, making easier to become publically available and to be used for 
research purposes.  
Breast cancer 
Breast cancer GWAS summary statistics were obtained from data published as part of the 
BCAC consortium, based on the iCOGS and the OncoArray genotyping arrays (see section 
3.1.3). 
Celiac disease  
GWAS summary statistics for celiac disease (133,352 SNPs) were downloaded from the 
ImmunoBase (https://www.immunobase.org/), a web based resource focused on the genetics 
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and genomics of immunologically related human diseases.  Celiac disease data has been 
reported in a GWAS study by Trynka and colleagues[144] on 12,041 celiac disease cases and 
12,228 controls of European ancestry using the Illumina Infinitum High-Density array 
(ImmunoChip), designed to target 195,806 SNPs located at immune-related genome 
regions.[145] 
3.2.5 Gene expression data: tumor RNA sequencing 
3.2.5.1 LIBRO-1/KARMA dataset 
Genome-wide expression data was measured for a subset of LIBRO-1 and KARMA patients. 
This subset of tumors were sequenced under two sequencing initiatives: the ClinSeq,[146] and 
the SCAN-B.[147] In brief, total RNA was extracted from tumor samples using ribosomal 
depletion (RiboZero; Illumina, US) in the ClinSeq study, and a poly-A enrichment dUTP 
library protocol in the SCAN-B. High quality RNA (RIN > 7) was assured. RNA sequencing 
was performed using the Illumina HiSeq technology. At minimum, more than 5 million paired-
end RNA fragments (reads) were obtained on each samples, and less than 60% duplication, 
meaning that a unique read is mapped twice.  
Quantification of gene expression levels was performed using a fast-alignment algorithm 
(quasi-mapping based mode), Salmon version 0.9.1.[148] For that, an index reference 
transcriptome (genome assembly version GRCh38) was built using the --type quasi -k 19 flag. 
Then, transcript-level estimates were extracted using the tximportData R package, and 
aggregated into gene-level expression values using the tximport R package.[149] Because the 
SCAN-B library protocol was design to target mRNAs, we filtered approximately 19,000 gene-
coding mRNAs in both datasets. 
3.2.5.2 External datasets 
Two external gene expression datasets were used as validation sets. A publically available 
breast cancer cohort from the TCGA database[152]  was used in Papers II and III, and a nested 
breast cancer cohort of the MERCK study, which has been previously described [127, 150, 
151] was used in Paper III. In brief, the TCGA dataset consisted of 975 primary invasive breast 
cancer tumors, from women of age 26 to 90 years. Pre-processed RNA-sequencing data, in 
form of transcript count computed with HTseq software,[153] was available for retrieval trough 
the GDC Data Transfer Tool. Data was downloaded on November 7th, 2018, together with 
patient clinical information. The MECK study comprised of 621 patients diagnosed with 
invasive and metastatic breast cancer, from which we identified 111 interval cancer and 109 
screen-detected breast cancers. In these samples, gene expression was measured using an 
Affymetrix microarray assay. 
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3.3 SUMMARY VARIABLES  
Variables that combine information from accumulated knowledge have the potential to 
improve our ability to evaluate the relationship between multiple factors involved in complex 
traits such as breast cancer. Particularly important are predictions on aggressive subtypes. In 
the following subsections summary variables used in this thesis are described. These include 
breast cancer risk scores (genetic and non-genetic), as well as gene expression patterns related 
to the disease aggressiveness (gene expression profiles and breast cancer subtypes).  
3.3.1 Protein-truncating variants (Paper I) 
Protein-truncating variants (PTVs) in 31 breast cancer genes sequenced on a gene panel 
(section 3.2.4.1), were used to summarize breast cancer genetic load by rare deleterious 
variants. PTVs were defined as variants disrupting gene function by introducing a stop codon 
(nonsense mutation), by frameshift insertion/deletions, or through splice site mutations.  For 
BRCA1/2 genes, PTVs annotations were refined based on previously confirmed nonsense and 
frameshift mutations,[154]  as well as missense pathogenic variants in BRCA1/2 genes 
confirmed by the ENIGMA international expert panel (http://brcaexchange.org/). The Maftools 
software[155] was used for summary, analysis, and visualization of the annotated variants. 
PTV carriership was defined as having at least one PTV in any of the 31 genes included in the 
gene panel, and was analyzed as a binary exposure. 
3.3.2 Polygenic risk score (Paper I and IV) 
A PRS is a tool to summarize the small effects of multiple loci associated with a polygenic 
disease,[156] and has potential clinical applications.[157] PRSs are calculated as a weighted 
combination of the number of risk alleles an individual has, where the weights/effect size 
estimates are typically obtained from an independent study population.[67] In Paper I, we 
included 162 GWAS significant (P-value < 5×10-08) SNPs associated with breast cancer. In 
Paper IV, we computed PRSs based on 199, 276, 1284, and 3803 SNPs associated with celiac 
disease, selected under four P-value thresholds (5×10-08, 1×10-05, 1×10-02, 5×10-02), 
respectively. 
We computed each PRS under the following multiplicative (log-additive) model: 
PRS = 𝛽1𝑥1 + 𝛽2𝑥2 + ⋯ + 𝛽𝑛𝑥𝑛 
where 𝛽𝑘 (𝑘 = 1, ⋯ , 𝑛) is the per-allele log-odds ratio, 𝑥𝑘 is the number of risk alleles (e.g. 0, 
1, or 2) for SNP𝑘, and n is the number of SNPs included in the PRS. The model assumes no 
genetic interactions, an assumption which has been shown to be reasonable.[158, 159] 
3.3.3 Tyrer-Cuzick risk score (Paper II) 
In Paper II, we measured the risk of women to develop breast cancer expressed as 5-year 
absolute risk. The risk was calculated using the Tyrer-Cuzick (TC) model,[160] a breast cancer 
risk assessment tool from the International Breast Cancer Intervention Study (IBIS). We 
entered information about established risk factors of breast cancer into the model. These 
 27 
included factors related to an increased lifetime endogenous estrogen exposure (i.e. early age 
at menarche, late age at first birth, late age at menopause), as well as exogenous exposures (i.e. 
use of oral contraceptives, and have undergone hormone-replacement therapy), to previous 
benign breast disease including hyperplasia, atypical hyperplasia, and lobular cancer in situ, in 
addition to height, weight, family history of breast and ovarian cancer, Ashkenazy descent, and 
BRCA mutation status.  
In brief, the TC model estimates the probability of a woman to develop breast cancer within 5 
years, 10 years, or during her lifetime. The risk is age-specific, which is calculated by 
considering the incidence rate of breast cancer at five year interval observed in the background 
population (e.g. UK or Sweden). The model multiplies the age-specific incidence by the 
probability of carrying a hypothetical predisposition gene accounting for all unknown 
predisposition genes explaining the familial aggregation. This probability is derived from 
BRCA frequencies in the population using a Bayes theorem. We computed the scores using the 
IBIS tool version 7 (http://www.ems-trials.org/riskevaluator/). 
3.3.4 Gene expression profiles (Paper II and III) 
In Paper II and III, we profiled tumors based on gene expression patters associated with breast 
cancer risk (Paper II) or with interval breast cancer (Paper III). The profiles included genes 
showing strongest association with the exposure of interest, and were computed as the 
following: 
Profile = 𝑊1𝑔1 + 𝑊2𝑔2 + ⋯ +  𝑊𝑛𝑔𝑛 
where 𝑊𝑘 (𝑘 = 1, ⋯ , 𝑛) is the gene weight obtained from the discovery gene expression 
analyses (explained in section 3.5.4), 𝑔𝑘 are the log2-scaled and normalized gene expression 
levels for gene k, and n is the number of genes included in the profile. 
3.3.5 Molecular subtypes (Paper II and III) 
In Paper I, surrogate molecular subtypes were assigned to samples using a machine learning 
algorithm fed with data on immunohistochemistry marker status (ER, PR, HER2, and ki67) as 
previously implemented by our group.[47]  
In paper II and III, breast cancer intrinsic molecular subtypes, also known as PAM50 subtypes, 
were inferred from gene expression data using a research-based classifier, the Absolute 
Assignment of Breast Cancer Intrinsic Molecular Subtype (AIMS).[161] This machine 
learning algorithm was developed to assign subtypes based on a set of patient-level gene 
expression rules, which are not affected by differences in array/sequencing platforms and 
cohort composition, both of which the PAM50 classifier is sensitive to. 
3.3.6 Immune subtypes (Paper III) 
Tumors were classified into distinct immune subtypes based on gene expression profiles 
following methodology published by Amara and colleagues.[162] The underlying principle is 
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that it is possible to extract immune-related signals from “bulk” RNA sequencing data. In that 
paper, the authors assessed 57 published immune expression signatures that could be assigned 
into one of four co-expression modules: core-serum response (CSR), T-cells and/or B-cells 
(T/B-cell), interferon (IFN), and transforming growth factor beta (TGFB). Using hierarchical 
cluster analysis,[163] samples could be classified based on five immune subtypes representing 
coherent immune-related expression patterns: Immune Low, CSR-High, IFN/CSR High, T/B-
Cell/IFN High, and TGFB High.  
3.4 STUDY DESIGNS 
3.4.1 Case-only study (Paper I-III) 
In Papers I to III, we used a case-only design in order to study patterns of breast cancer 
aggressiveness. In this way, we could assess whether differences in adverse outcomes (more 
aggressive vs. less aggressive) defined by a number of prognostic factors (e.g. ER-negative 
tumors), could be explained by a variable of interest (exposure). In this thesis, we evaluated 
exposures such as different types of breast cancer genetic load (Paper I), level of non-genetic 
breast cancer risk (Paper II), and unfavorable mode of detection (Paper III).  
3.4.2 Case-control study (Paper IV) 
Case-control studies are meant to evaluate the association between a variable of interest 
(exposure) and the disease status (cases or disease-free controls). In Paper IV, we used this 
study design to estimate breast cancer risk by the amount of genetic predisposition to celiac 
disease. The main difference with case-only studies, is that the reference (control) group is 
comprised of non-affected individuals. This approach offers a cost-effect strategy to quantify 
whether an exposure variable is likely to reduce or increase the probability of developing a 
disease. A higher level of scientific evidence stems from prospective cohort studies and from 
randomized-control trials, however, these study designs are costly and often not viable. 
3.4.3 Genetic correlation and overlap (Paper IV) 
In Paper IV, we performed analysis on the shared genetic component between breast cancer 
and celiac disease, using two type of methods: 1) based on raw genotype data we computed a 
celiac disease PRS (see section 3.3.2), which was then used to estimate risk to develop breast 
cancer, and 2) estimation of genetic correlation and overlap based on analysis of GWAS 
summary statistics (section 3.2.4.3) using methods described in sections 3.5.6 and 3.5.7. In 
brief, this type of study aim to assess the extent of genetic variation that is shared between 
polygenic traits (e.g. complex diseases). Ideally, genetic variation on each trait should be 
measured using set of samples independent from the discovery studies in order to avoid over-
estimation. The existence of a widespread shared genetic variation across complex traits is 
based on the concept of pleiotropy, meaning that genetic variants can be involved in multiple 
disease pathways.[164] In essence, genetic overlap is similar to the concept of pleiotropy, while 
in genetic correlation analysis the direction of the association is taken into account.[98] Future 
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studies might explore the role of cell-type or tissue specific effects on the genetic predisposition 
shared between different diseases.[165]   
3.5 STATISTICAL METHODS 
All statistical analyses were performed in the open-access statistical software R. Binary 
outcomes were analyzed using logistic regressions, and categorical outcomes using 
multinomial logistic regressions. Survival analyses were performed using Cox regressions. 
Methods to analyze gene expression differences and their effect at the level of biological 
processes, are also included. Finally, methods to assess genetic correlation are described, as 
well as modeling of potential confounding. 
3.5.1 Logistic regression 
Logistic regression was used to make inference on binary variables (outcomes) such as ER-
negative vs ER-positive status or interval cancer vs screen-detected tumor. Effect estimates for 
the associations of explanatory variables (exposures) such as high vs low PRS, or carriership 
of rare variants, with the main outcomes, were expressed as odds ratios (OR), and 95% 
confidence intervals, were calculated. With logistic regression, the probability of an event Y 
(binary outcome), conditional on an explanatory variable, X, is modelled as 
𝑃(𝑌 = 1|𝑋) = 𝑃(𝑌) =  
𝑒(𝛽0+𝛽1𝑋)
1 +  𝑒(𝛽0+𝛽1𝑋)
 
where 𝛽0 and 𝛽1are two parameters inferred from the data, e is the exponential, and X is a 
covariate (but can easily be extended to a set of covariates). The log-odds is defined as 
 𝑙𝑜𝑔 [𝑃(𝑌)  1 − 𝑃(𝑌)]⁄ , which is known as the logit transformation. It can be shown that 
unbiased estimates of ORs can be obtained from case-control data by fitting a logistic 
regression model and by taking the exponent of the estimate of 𝛽1. Under this model, 𝛽1 
represents the log-odds ratio, and is defined as 𝑙𝑜𝑔[𝑜𝑑𝑑𝑠 𝑜𝑓 𝑌 | 𝑋 = 1 𝑜𝑑𝑑𝑠 𝑜𝑓 𝑌 | 𝑋 = 0⁄ ]. 
Logistic regression models were fitted as special cases of generalized linear models using the 
R function glm. 
3.5.2 Multinomial logistic regression 
Multinomial logistic regression was used to estimate ORs, with 95% confidence intervals, 
when assessing association with categorical outcome variables (reference category vs exposure 
categories), using the nnet R package. The multinomial regression model can be viewed in 
terms of separate logistic regression models for each exposure category, each against the 
reference group. 
3.5.3 Cox Proportional-Hazards regression 
Cox Proportional Hazards (PH) regression was used to estimate hazard-ratios (HRs), with 95% 
confidence intervals. Under this method, a time-to-event (e.g. from death due to breast cancer) 
is modeled as a function of explanatory variables, and individuals are considered to be at risk 
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from the time to entry to the end of follow up, and are censored (no longer considered as risk) 
if the event has occurred, the participant has left the study, or the study has ended. The Cox PH 
regression model specifies the hazard of an event at time t as a function of a baseline hazard 
and the independent explanatory variable(s), such that 
𝜆(𝑡|𝑋𝑖) = 𝜆0(𝑡) exp(𝑋𝑖 ∙  𝛽) 
where 𝜆0(𝑡) is the baseline risk of the event (i.e. with covariates set to zero) per unit change in 
the underlying time scale, 𝑋𝑖 is the vector of covariates for i individuals, and 𝛽 is the vector of 
coefficients explaining the hazards. In our analysis, time since diagnosis, in years, was used as 
the underlying time scale. 
3.5.4 Gene expression analysis  
Gene expression analysis were performed in Papers II and III to quantify gene-level differences 
across samples explained by the exposure of interest. Methods under the generalized linear 
model framework that allowed for including co-variates were developed to analyze gene 
expression levels in the form of intensities yielding from Microarray platforms.[166] With the 
advent of RNA-sequencing technologies, which instead produces count data (e.g. number of 
RNA fragments mapped into a gene-coding region), new types of statistical model have been 
required. In our studies, we used the methodology implemented in the edgeR package,[167, 
168] which is based on the negative binomial distribution and quasi-likelihood tests. Data 
preprocessing included normalization for differences on library composition (e.g. amount the 
RNA fragments) using the trimmed mean of M-value method.[169] 
3.5.5 Gene set enrichment analysis (GSEA) 
Gene set enrichment analysis (GSEA) methods assess the information coherence at gene level 
(association with a given trait) when grouped into gene sets defined based on prior knowledge 
(gene annotations). In this thesis, we used a well curated annotation source, the Molecular 
Signature Database (MSigDB) comprised of fifty biological hallmark gene sets (not to be 
confused with the hallmarks of cancer!).[170] Generally, gene sets are said to be enriched if 
there is significant statistical evidence that its constituent genes are differentially expressed in 
a consistent manner. Since a number of GSEA methodologies have been developed based on 
different statistical assumptions and hypothesis testing,[171, 172] one approach is to look for 
consistent results produced by different methods. 
In Papers II and III, we used a comprehensive workflow analysis implemented in the Piano R 
package.[173] The input data is described on each paper. Gene set-level statistics were 
computed using six different GSEA methods: Wilcoxon rank-sum test, tail strength, mean, 
median, sum, reporter features, and Stouffer’s method. To summarize findings, the Piano 
workflow generates a consensus score to rank gene set based on their consistency for 
association across the different GSEA methods.  In addition, gene set enrichment is 
distinguished by the direction of gene expression changes (e.g. positive or negative) into: non-
directional class (only gene-level P-value information is considered), mixed-directional class 
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(gene set can have subset of genes associated in opposite directions, one of which dominates), 
and distinct-directional class, which indicates a clear trend for association in either direction 
(genes associated in opposite direction will cancel each other out). Statistical significance was 
assessed based on the null distribution computed by permutation of gene labels. To control for 
multiple testing, we allowed the false discovery rate (FDR) to be lower than 5%. Significantly 
enriched gene sets were reported as having a median adjusted P-value lower than 0.05. 
3.5.6 Cross-trait LD Score (LDSC) regression  
In Paper IV, we used LDSC regression to estimate genetic correlation.[98] This method is 
based on modeling GWAS summary statistics based on LD (linkage disequilibrium).[98, 174] 
LD is the non-random association of alleles at different loci (the combinations of alleles at 
different loci on the same chromosome are called haplotypes). If two SNPs were independent 
and associated randomly, for alleles A1 and A2 at locus A, with respective frequencies 
𝑝𝑖(𝑖 = 1,2), and alleles B1 and B2 at locus B, with frequencies 𝑞𝑘(𝑘 = 1,2), the expected 
haplotype probabilities would be defined by 𝑝𝑖 × 𝑞𝑘.[141] LDSC regression is based on 
modeling the genetic covariance as the relationship between SNP effect estimates for two traits 
(i.e. the product of z scores, 𝑧1𝑗𝑧2𝑗 for SNP j) explained by the amount of information, LD 
score, SNPs carry. In such a case, the LDSC regression assumes that an SNP in high LD with 
other SNPs summarizes the effects those SNPs. The LDSC regression is estimated in such a 
way that the expected value of 𝑧1𝑗𝑧2𝑗 is regressed on the LD scores, under the equation 
𝐸[𝑧1𝑗𝑧2𝑗| ℓ𝑗] =
√𝑁1𝑁2 𝜚ℊ
𝑀
ℓ𝑗 +
𝜚𝑁𝑠 
√𝑁1𝑁2
 
where 𝑁𝑖 is the study sample size, 𝜚𝛿 is the genetic covariance, ℓ𝑗 is the LD score, 𝑁𝑠 is the 
total number of individual, 𝜚 is the phenotypic correlation among 𝑁𝑠 overlapping samples, and 
𝑀 is the number alleles in the reference panel with minor allele frequency between 5% and 
50%. Genetic correlation is then calculated as 
𝑟ℊ ∶= 𝜚ℊ √ℎ1
2ℎ2
2⁄  
where the genetic covariance 𝜚ℊ is normalized by the SNP heritabilities ℎ𝑖
2 from study i. 
3.5.7 SNP Effect Concordance Analysis (SECA)  
In addition to the LDSC regression used in Paper IV, we measured genetic correlation and 
overlap using the SECA methodology,[96] which is based on a different statistical approach. 
While in the LDSC regression genetic correlation is modelled as a function of the LD scores, 
the SECA method is based on a pre-selection of independent SNPs (e.g. in low LD with each 
other) so that genetic correlation is not inflated by SNPs in high LD. SNPs are filtered using a 
two-step LD pruning procedure. Of notice, genetic correlation is referred as genetic 
concordance under this method.  
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In order to assess the genetic shared component between two traits, effect estimates (P-values) 
from each trait (Pi) are plotted against each other into a grid. The grid consist of 144 squares 
defined by combinations of 12 x 12 equally increasing P-value thresholds: {𝑃1, 𝑃2} =
 {0.01, 0.05. 0.1, 0.2, 0.03, … , 1.0}, where the strongest evidence of genetic overlap would be 
expected to occur at the lowest P-value combination {𝑃1 < 0.01, 𝑃2 < 0.01}. Genetic overlap 
is defined as the excess in overlapping SNPs (observed > expected) across the grid assessed 
through binomial tests. To avoid overestimation due to powered GWAS yielding low P-values, 
the expected frequency of overlapping SNPs is defined as the observed frequency for one of 
the traits. In paper IV, we used the observed proportion of celiac disease SNPs as the expected 
value. Analogous to genetic correlation, SECA test assess for consistency in the direction of 
effects between overlapping SNPs through Fisher’s tests across the P-value grid. An odds ratio 
> 1 indicates genetic concordance (e.g. positive correlation), < 1 indicates genetic discordance 
(e.g. negative correlation), and an odds ratio equal to 1 means no evidence of genetic 
correlation. Significance testing was performed by generating empirical null distribution 
through random permutation of SNP effect estimates. Following the SECA approach, the 
subset of overlapping SNPs with strongest evidence of genetic correlation can be identified. 
3.5.8 Confounding 
Because of the cross-sectional nature of case-only and case-control studies, potential 
confounding effects are of major concern. Confounding variables are factors correlated with 
both the exposure and the outcome, and that lead to spurious associations or masked effects 
(biased estimates) when not taken into account. Modeling of covariates and stratified analysis 
are two common approaches to deal with potential confounding. We used both approaches in 
this thesis, while crude effects were obtained from unadjusted analyses. The main confounding 
variables were: chronological age, age at breast cancer diagnosis, PAM50 subtypes, 
mammographic density, tumor characteristics, and treatment. In genetic correlation analysis, 
the effect of phenotypic covariates is assumed to be minimal, and other sources of confounding 
such as genetic correlation by sample overlap or relatedness, and LD structure, are considered 
under each methodology. 
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4 MAIN RESULTS AND INTERPRETATIONS 
 
Unlike common genetic variation, carriership of rare deleterious variants in breast 
cancer predisposition genes was associated with more aggressive tumors and poorer 
survival. 
In Paper I, we analyzed the contribution of germline genetic variants towards disease 
aggressiveness in a case-only study. We found that common genetic variants tend to predispose 
to tumors of more favorable clinicopathology, whereas rare deleterious variants were 
associated with more aggressive disease defined by tumor characteristics and the PAM50 
subtypes (Figure 6). In particular, stronger differences were observed for tumor grade, luminal 
B, and basal-like subtypes. Of note, we did not observed differences in common genetic load 
(i.e. for overall, ER-positive, and ER-negative PRS) by rare variant carriership status (see paper 
I, Figure S3). In addition, rare deleterious variants in any of the 31 breast cancer genes, PTV 
carriership, was associated with interval cancers in women with low mammographic density, 
as well as with worse survival independently of treatment and tumor characteristics (see paper 
I, table 3 and 4). The strongest association with worse survival was observed for women below 
age 50 and carriers of non-BRCA1/2 rare variants, whereas no association was observed for 
common variants. Likewise, BRCA1/2 rare variants seemed to drive the association with ER-
negative and basal-like subtypes in younger women (OR: 1.75; 95% CI, 1.11 to 2.75, and OR: 
5.24; 95% CI, 2.35 to 11.66, respectively), and this is consistent with previous knowledge about 
the enrichment of BRCA1 variants in basal-like tumors. Interestingly, non-BRCA1/2 rare 
variants remained significantly associated with poorly-differentiated and luminal-B tumors in 
older women (OR: 1.65; 95% CI, 1.10 to 2.48, and OR: 2.21; 95% CI, 1.36 to 3.59, 
respectively). Together, our analysis indicates that carriership of rare deleterious variants in 
any of the 31 predisposition genes predispose to more aggressive disease, independently of age 
group. 
Discussion 
In our study, we leveraged large genotyping data and previous GWAS findings in order to 
compute genetic risk scores, as well as on targeted exome sequencing to inquire into rare 
deleterious mutations. Our findings suggest that rare and common variants act as distinct risk 
entities. This is consistent with the hypothesis that rare predisposition mutations with moderate 
effects (e.g. heterozygous mutations in genes for which biallelic mutations are known to be 
causal of genetic syndromes) are more likely to explain the missing heritability observed in 
GWAS studies.[175] However, there are some methodological challenges in interrogating the 
contribution of rare variants using NGS technologies, such as low power.[176] To overcome 
that, we used an approach by aggregating mutations. Thus, we assumed that predisposition to 
breast cancers of an aggressive phenotype could occur through disruption of any of the genes 
tested. 
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In that context, the association of rare variants with unfavorable disease outcomes suggests a 
direct link to the etiopathology of breast cancer. Because the analyzed genes are involved in 
important processes of genome maintenance such as DNA-repairing mechanisms,[177] 
deleterious mutations in any of these genes could increase the probability to develop more 
aggressive tumors by acquisition of further mutations. Interestingly, a recent whole-exome 
sequencing study of 54 non-BRCA familial breast cancer index patients found that 44% of 
them carried one or maximum 3 rare deleterious variants.[178] The authors reported that 
mutations in DNA repairing genes conferred a two-fold increased risk as compared to 120 
matched controls, and novel variants in genes not known to be related to cancer were found, 
highlighting the usefulness of sequencing approaches. 
Regarding common variants, their utility to predict risk to develop either breast cancer subtype, 
will require the incorporation of subtype-specific risk variants identified through ongoing 
efforts, particularly of triple-negative breast cancer,[63] and as shown in the latest 
comprehensive GWAS published in May, 2020.[61] As noticed in our analysis, genetic load 
from common variants weighted by ER-negative disease did not show association with 
unfavorable prognosticators, and although correctly predicted higher risk for ER-negative 
disease, had a small effect (ORper1-SD: 1.10, 95% CI, 1.01 to 1.19). In the contrary, analysis 
based on variants weighed by ER-positive disease showed similar associations as weighting by 
the overall risk, supporting the idea that discovery based on overall breast cancer is biased 
towards the most frequent ER-positive disease.  
 
Lower breast cancer risk defined by the Tyrer-Cuzick score was associated with more 
aggressive disease. Gene expression analysis highlighted the involvement of proliferative 
processes. 
In Paper II, we found that breast cancer risk defined by the TC score was inversely associated 
with basal-like and HER2-enriched surrogate subtypes (as compared with luminal A surrogate 
subtype), and with ki-67 proliferative marker. In order to better understand the association 
between lower TC and disease aggressiveness, we characterized underlying molecular 
differences. Using transcriptomic data, we correlated gene expression to TC score and 
summarized it into a low-risk TC-expression profile (TC-Gx), based on the top 37 genes 
showing strongest correlation with TC. The low-risk TC-Gx was able to discriminate tumors 
and indicated an overlap with more aggressive subtypes, particularly with basal-like tumors 
(Figure 7). Regression analyses showed that the low-risk TC-Gx was associated with the more 
aggressive PAM50 subtypes such as basal-like (validation dataset, OR per1-SD: 13.20, 95% 
CI, 7.10 to 24.57) and HER2-enriched (validation dataset, OR per1-SD: 4.79, 95% CI, 2.95 to 
7.79) as compared with luminal A tumors, and with higher breast cancer-specific mortality 
(≥mean vs <mean low-risk TC-Gx, HR: 2.29, CI, 1.21 to 4.35). The association with higher 
mortality was partially explained by the PAM50 subtypes and by higher levels of ki-67 gene 
expression, but not by ER expression. Interestingly, we found that low-TC gene expression 
was significantly enriched in proliferative and oncogenic signaling processes. 
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Figure 6. Differential association of rare and common genetic variants with breast cancer 
aggressiveness. Rare variants are represented by carriership of at least one PTV in any of the 
31 panel genes (violet) or excluding BRCA1/2 variants (blue). Common variants are depicted 
by overall (green), ER-positive (mustard), and ER-negative (orange) PRSs. 
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Figure 7. Relationship between low-risk TC-Gx profile and breast cancer intrinsic subtypes. 
Principal Component Analysis (PCA) plot showing similarity between 296 samples in the 
discovery set based on transcriptomic data (whole-genome expression levels). Samples are 
labeled according to the low-risk TC-Gx profile: open square if decreased (< mean distribution) 
or solid dot if increased (≥ mean distribution). In addition, tumor samples are colored to show 
their relationship with intrinsic subtypes. 
 
Discussion 
In our study, we used a molecular epidemiology approach to investigate gene expression 
features behind the association of low TC score with the breast cancer subtypes of unfavorable 
prognosis, and this is consistent with previous work from our group.[38] In addition, our low-
risk TC-Gx was found to be associated with worse survival independently of ER status, 
suggesting the existence of underlying risk factors beyond the involvement of estrogen 
exposure. Therefore, risk modeling incorporating factors associated with basal-like and HER2-
enriched disease, and in particular risk factors favoring higher proliferation, could have an 
important contribution to improve risk assessment tools. Interestingly, the association between 
low-risk TC-Gx and survival was only weakened after adjusting by the PAM50 subtypes and 
high proliferation status, indicating the existence of poor prognosis tumors within the Luminal 
A subtype. 
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Findings from our enrichment analysis highlighted oncogenic and signaling pathways as 
potential mechanisms underlying the increased aggressiveness associated with low TC. 
Interestingly, these included MYC and E2F oncogenic targets, as well as mTORC1 and WNT 
beta catenin pathways, which have been associated with aggressive breast cancer subtypes. For 
instance, MYC overexpression has been associated with poorer outcomes in basal-like, 
Luminal A breast cancer with lymph-node involvement, and HER2-postive tumors,[179], 
whereas E2F transcription factors, mTORC1 and WNT beta catenin, have been found to be 
important in triple-negative breast cancer.[180-182] 
The TC model, similar to other risk assessment tools (such as the Gail model, and genetic 
scores), can be used to stratify women into distinct risk groups. This stratification can be used 
to tailor preventative strategies. For instance, women with a risk higher than the average risk 
observed for their age-group, could be considered for personalized screening,[183] so that early 
detection is achieved more successfully in the entire screening population. We argue that in 
order to effectively reduce disease mortality, risk assessment tools should be able to identify 
women at increased risk of developing breast cancer aggressive subtypes. 
 
Compared to screen-detected tumors, interval cancers in women with low-dense breasts 
exhibited gene expression patterns associated with interferon immune subtypes, 
independently of PAM50 subtypes. 
In Paper III, we characterized gene expression for interval cancer in women with low-dense 
breasts as compared with screen-detected tumors, in order to identify underlying biological 
features independently of the PAM50 subtypes. Through enrichment analysis using the 
MSigDB database, a curated collection of hallmark gene sets representing well-defined 
biological processes, we found that altered gene expression in interval cancers was mainly 
related to immune response. We then profiled tumors based on genes found to be strongly 
associated with interval cancer by computing the IC-Gx profile. The IC-Gx was found to be 
associated with breast cancer subtypes, particularly with subtypes involving a high interferon 
signal, and this was replicated in an independent cohort from the TCGA database (Figure 8).   
Discussion 
It is not well understood why some tumors, referred as interval cancers, are less likely to be 
detected through regular mammographic screening. Because interval cancers tend to be have 
more adverse tumor characteristics,[184] and molecular subtypes[185] one hypothesis is that 
fast growing tumors commonly of ER-negative, basal-like and HER2-enriched subtype, are 
able to reach symptomatic detectability in a short time spam and therefore are more likely to 
become interval cancer. Another complementary hypothesis is that high mammographic 
density, which is associated with interval cancers,[186, 187] reduces mammographic screening 
sensitivity, also known as masking effect.[33] Nevertheless, in addition to conventional tumor   
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Figure 8. Association between the IC-Gx profile with breast cancer subtypes. A) Association 
with immune subtypes as compared with the Immune Low subtype, and adjusted for PAM50 
subtypes. CSR, core-serum response; T/B-cell, T-cells and/or B-cells; IFN, interferon; TGFB, 
transforming growth factor beta. B) Association with main intrinsic subtypes as compared with 
the Luminal A subtype. In both figures, estimates were obtain from multinomial logistic 
regressions in the discovery (LIBRO-1/KARMA, n=672) and external validation set (TCGA, 
n=975). Odds ratio and 95% confidence intervals are shown per one-standard deviation in the 
IC-Gx profile.  
 
characteristics, other factors are needed to be discovered in order to explain the poorer 
outcomes observed for interval cancer.[188]  Previous work from our group have shown that 
aggressive interval cancers are over represented in women with mammographically low dense 
breasts.[38] Also, molecular characterization of interval cancers lead to the conclusion that 
most features were explained by the PAM50 subtypes.[37]  
In order to improve early detection of breast cancer, better biological understanding of interval 
cancers is needed.[189] By dissecting gene and molecular process likely to underlie interval 
cancers, our study contributes toward this goal. In particular, our study highlights the 
involvement of the interferon immune response as a potential target. These findings are further 
supported by preliminary data from our group showing that germline genetic variants 
associated with interval cancers are significantly enriched in a network of IC-Gx genes 
(CXCL7/8, CXCR1/2) interacting with type I and II interferon genes. To our knowledge, this is 
the first study to characterize gene expression patterns on interval cancers in women with low 
dense breast, and to bring forward the potential role of interferon genes into this subset of 
aggressive breast cancers. 
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Shared common genetic variation between breast cancer and celiac disease was found to 
be inversely correlated, consistent with previous epidemiological findings on the reduced 
risk of breast cancer in celiac disease patients.  
In Paper IV, we measured the extent of the shared genetic variation between breast cancer and 
celiac disease, guided by previous epidemiological findings on the observed reduced risk of 
breast cancer in celiac disease patients. We found a statistically significant inverse genetic 
correlation between the two diseases using two different analytical approaches (overall breast 
cancer and celiac disease, LDSC, r = -0.17, s.e. 0.05; SECA, OR: 0.60, 95% CI: 0.44 to 0.82). 
In a third analysis, we performed a case-control analysis to estimate breast cancer risk by celiac 
disease genetic load, namely, celiac disease polygenic risk score (celiac-PRSs). We found that 
a higher genetic load for celiac disease was associated with 6% to 13% decrease risk of breast 
cancer when comparing highest versus lowest quartile distribution (quartile 4 vs. quartile 1 of 
celiac-PRS based on 3,803 associated with celiac disease at nominal P-value, OR: 0.83, 95%CI 
0.75 to 0.93). Associations by ER status showed similar results between overall breast cancer 
and ER-positive disease, whereas no association was observed for ER-negative breast cancer, 
nor for other tumor characteristics. Further assessment of the genetic overlap between the two 
diseases showed that top SNPs were significantly overrepresented in pre-defined gene sets such 
as: induction of apoptosis and programmed cell death, MAPK and other protein-protein 
interaction subnetworks, as well as gene sets related to immune phenotypes. A prioritization 
analysis highlighted fifteen top SNPs as the most relevant loci for the genetic overlap between 
the two diseases (Figure 9). 
Discussion 
The immune system has an important role in breast cancer, both in the etiology and the 
progression of the disease.[126, 190] As a strategy to investigate the immune-related genetic 
component in the etiology of breast cancer, we exploited potential pleiotropic effects with 
celiac disease by leveraging of the largest GWAS summary statistics from breast cancer and 
celiac disease available at the time. Our findings were consistent with the observed reduced 
risk of breast cancer in celiac disease patients, which has been reported to be 10% to 15% 
lower, in Nordic populations.[92-94, 191] In addition, we pinpointed genetic loci and 
molecular pathways as most likely underlying a shared etiology between the two diseases. Our 
findings forward the hypothesis that an increased genetic susceptibility to celiac disease could 
be protective against breast cancer pathogenesis by regulation of key immune processes 
directing cancer cells towards apoptosis, in which immunesurveillance processes can prevent 
mammary cancer cells to proliferate.[192] Likewise, an unfavorable immune-related genetic 
load could be involved in the breast cancer etiopathology by predisposing mammary cancer 
cells to evade the immune system. It is possible that an increased propensity for the formation 
of cancer cells (such as mutations in genome-stabilizing genes), together with an altered 
immunogenic microenvironment, could lead towards an equilibrium phase of cancer cells with 
the host immune system. In such a phase, cancer cells would adapt and acquire further 
mutations favoring tumor development.[125] 
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Figure 9. Network of the 15 immune-related genes most likely to underlie the genetic overlap 
between breast cancer and celiac disease. Genes were deemed as significantly relevant (P-
value<0.05) in a prioritization analysis from a list of 52 top-overlapping SNPs between breast 
cancer (BC) and celiac disease (CD) (PBC≤0.05, PCD<1×10-05), and are described in Paper IV, 
Table 3. Gene network was generated based on known gene-gene interactions using 
STRINGv11.[193] 
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5 Concluding remarks 
i. The study of breast cancer genetic germline variants is useful to improve our clinical 
and biological understanding of the disease, particularly when linked to detailed 
phenotypic data. 
ii. We observed that unlike common variants, rare deleterious variants in breast cancer 
predisposition genes were associated with more aggressive disease. This supports the 
hypothesis that rare variants with moderate penetrance in key pathways have an 
important contribution in the disease progression. 
iii. The observed association between lower risk of breast cancer with more aggressive 
disease, is likely due to the lack of accuracy to predict highly proliferative and invasive 
tumors by means of established risk factors (non-genetic) as modelled in the Tyrer-
Cuzick score. 
iv. Interval breast cancer, a subset of tumors not detected at the time of regular 
mammographic screening visits, was found to display unique gene expression patterns 
correlated with interferon-immune response that could be involved in their aggressive 
phenotype. 
v. The potential role of an inherited immunogenic environment in the etiology of breast 
cancer was highlighted by our findings on the shared genetic component with celiac 
disease, an autoimmune disease.  
vi. Findings in this thesis could inform further efforts toward the identification of women 
at high risk to develop aggressive breast cancer.
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6 Future perspectives 
After the conclusion of the four studies presented in this thesis, some questions come to light: 
Would rare deleterious variants be associated with breast cancer (subtype-specific) risk in a 
case-control study, or are these type of variants mainly contributing to the disease prognosis? 
Would sequencing of pairs of germline and somatic tissue show that protein-truncating variants 
become homozygous driver mutations, or that rather act through other mechanisms? 
What is the optimal genotyping strategy in breast cancer epidemiological studies needed to 
identify significant genetic variants associated with aggressive subtypes? Would well-powered, 
subtype-specific GWAS on basal-like, HER2-enriched, and highly proliferative tumors, be 
sufficient? Or are whole-exome and/or whole-genome sequencing approaches necessary to 
identify genes and regulatory regions implicated in the development of aggressive subtypes of 
breast cancer?  
Either way, large studies using surrogate subtype classifiers based on IHC markers, could be 
of great importance, while more refined analysis to understand additional biological aspects 
will require omics data such as gene expression. In that way, the discovery of novel risk factors 
specific to more aggressive disease subtypes and their incorporation into risk assessments tools 
will improve our ability to identify women at increased risk. 
Another future direction is whether existence of additional aggressive subsets of breast cancer 
require our attention, for instance therapy-resistant Luminal A tumors. Or, is that other 
aggressive features, such as unfavorable immune response and mutational load, act 
independently of phenotype from the PAM50 classification and are more important in this 
context?  
Our findings suggest that fine mapping of the genetic variation in immune-related genomic 
regions will be also useful to understand the role of the immune system in susceptibility to 
develop breast cancer. In addition, future genomic and functional studies are required to better 
understand the role of immune phenotypes in the disease progression of aggressive subsets 
such as interval cancers. For instance, are there specific interferon genes also associated with 
BC prognosis? If so, what are the mechanisms favoring tumor progression that could be 
targeted? 
Finally, because higher mortality is observed in non-European populations from often less 
socioeconomically developed countries, worldwide reduction of disease mortality will require 
the transfer of knowledge and improvements of their healthcare systems. 
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